larotaxel (XRP9881)

DRUG5 trials

Sponsors

Sanofi

Conditions

Advanced Breast CancerBreast CancerBreast NeoplasmsMetastatic Breast CancerPancreatic NeoplasmsUrinary Bladder Neoplasms

Phase 2

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

CompletedNCT00386685

SanofiBreast Neoplasms

Start: 2006-07-31End: 2011-01-31Updated: 2011-04-12

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

CompletedNCT00387907

SanofiAdvanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer

Start: 2006-10-31End: 2008-03-31Updated: 2016-05-05

Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients

CompletedNCT00485979

SanofiBreast Neoplasms

Start: 2007-06-30End: 2010-08-31Updated: 2011-06-28

Phase 3

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

CompletedNCT00417209

SanofiPancreatic Neoplasms

Start: 2006-12-31End: 2009-11-30Updated: 2016-06-03

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

CompletedNCT00625664

SanofiUrinary Bladder Neoplasms

Start: 2008-02-29End: 2011-02-28Updated: 2016-05-05